UNITED THERAPEUTICS Corp 4

United Therapeutics CEO Martine A. Rothblatt exercised 9,500 options at $135.42 and sold 9,500 United Therapeutics (UTHR) common shares around $534–$543 on July 13, 2026 pursuant to a 10b5-1 plan.

On July 13, 2026, United Therapeutics Corporation Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options at an exercise price of $135.42 per share, acquiring 9,500 shares of common stock, and on the same day sold those 9,500 shares in a series of open market transactions at prices between approximately $533.70 and $542.80 per share under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The gross sale proceeds were roughly $5.1 million, implying an approximate $3.8 million spread over the exercise cost. Following these transactions, she reported direct ownership of 40,513 common shares, and significant additional indirect holdings including 166 shares held by her spouse and multiple family trusts holding 324,443, 249,108, 45,596, and 8,902 common shares, plus stock options held in a family trust; the filing notes that the 10b5-1 plan will continue until the earlier of the exercise of 1,734,410 options expiring March 15, 2027 or December 31, 2026, indicating this is part of an ongoing, programmed diversification strategy rather than a one-off discretionary sale.

Filing Facts

CIK

1082554

Ticker

UTHR

Form

4

Source Type

fda

Accession

0001106578-26-000097

Alert Tier

7